Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressure
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Background: Clinical studies have shown that integrase strand transfer inhibitors can be used to treat HIV-1 infection. Although the first-generation integrase inhibitors are susceptible to the emergence of resistance mutations that impair their efficacy in therapy, such resistance has not been identified to date in drug-naïve patients who have been treated with the second-generation inhibitor dolutegravir. During previous in vitro selection study, we identified a R263K mutation as the most common substitution to arise in the presence of dolutegravir with H51Y arising as a secondary mutation. Additional experiments reported here provide a plausible explanation for the absence of reported dolutegravir resistance among integrase inhibitor-naïve patients to date. Results: We now show that H51Y in combination with R263K increases resistance to dolutegravir but is accompanied by dramatic decreases in both enzymatic activity and viral replication. Conclusions: Since H51Y and R263K may define a unique resistance pathway to dolutegravir, our results are consistent with the absence of resistance mutations in antiretroviral drug-naive patients treated with this drug.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Retroviral intasome assembly and inhibition of DNA strand transfer
Hare, S., Gupta, S. S., Valkov, E., Engelman, A., & Cherepanov, P. (2010) · Nature · doi:10.1038/nature08784 · Cited by 678 · cited 1×
“Molecular modeling of HIV integrase and DTG docking were performed with the PFV lead template structures PDBID: 3S3M [25] and PDBID: 3L2S [33] as previously described [17].”
MethodHare, S., Smith, S. J., Métifiot, M., Jaxa-Chamiec, A., Pommier, Y., Hughes, S. H., & Cherepanov, P. (2011) · Molecular Pharmacology · doi:10.1124/mol.111.073189 · Cited by 264
Hightower, K. E., Wang, R., DeAnda, F., Johns, B. A., Weaver, K., Shen, Y., Tomberlin, G. H., Carter, H. L., Broderick, T., Sigethy, S., et al. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00157-11 · Cited by 226
Cited by
Cahn, P., Pozniak, A. L., Mingrone, H., Shuldyakov, A., Brites, C., Andrade-Villanueva, J. F., Richmond, G., Buendia, C. B., Fourie, J., Ramgopal, M., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61221-0 · Cited by 516
Tsiang, M., Jones, G. S., Goldsmith, J., Mulato, A., Hansen, D., Kan, E., Tsai, L., Bam, R. A., Stepan, G., Stray, K. M., et al. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01474-16 · Cited by 290
Le Rouzic, E., Bonnard, D., Chasset, S., Bruneau, J.-M., Chevreuil, F., Le Strat, F., Nguyen, J., Beauvoir, R., Amadori, C., Brias, J., et al. (2013) · Retrovirology · doi:10.1186/1742-4690-10-144 · Cited by 127
Hassounah, S. A., Alikhani, A., Oliveira, M., Bharaj, S., Ibanescu, R.-I., Osman, N., Xu, H.-T., Brenner, B. G., Mesplède, T., & Wainberg, M. A. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01695-17 · Cited by 40
Self-citation
Metadata
- Authors
- Mesplède, T., Quashie, P. K., Osman, N., Han, Y., Singhroy, D. N., Lie, Y., Petropoulos, C. J., Huang, W., & Wainberg, M. A.
- Venue
- Retrovirology
- Published
- 2013-02-22
- Volume
- 10
- Issue
- 1
- Pages
- 22-22
- ISSN
- 1742-4690 (ISSN-L)
- OpenAlex
- W2110471430
- Cited by
- 131
- References
- 3
- FWCI
- 15.26
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressure. https://app.cochat.ai/papers/10.1186/1742-4690-10-22
- The paper
- Mesplède, T., Quashie, P. K., Osman, N., Han, Y., Singhroy, D. N., Lie, Y., Petropoulos, C. J., Huang, W., & Wainberg, M. A. (2013). Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressure. Retrovirology. https://doi.org/10.1186/1742-4690-10-22
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.